<DOC>
	<DOCNO>NCT00192465</DOCNO>
	<brief_summary>To provide safety , tolerability , pharmacokinetic , immunogenicity data MEDI-524 administer initially single dose healthy adult dose escalation safety study test target pediatric population .</brief_summary>
	<brief_title>Trial Evaluate Safety , Tolerability , Pharmacokinetics MEDI-524 Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Volunteers must meet following criterion : Age 18 49 year time administration study drug Weight £90 kg Healthy medical history physical examination Normal electrocardiogram ( EKG ) screening ( must within 21 day entry study ) Written informed consent obtain volunteer Sexually active female , unless surgically sterile , must use effective method avoid pregnancy ( include oral implanted contraceptive , IUD , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 14 day prior administration study drug , must agree continue use precaution 30 day administration study drug , must negative serum pregnancy test within 7 day prior administration study drug negative urine pregnancy test day study drug administration . Ability complete followup period 90 day ( singledose group ) 120 day ( twodose group ) require protocol Volunteers must none following : Acute illness time entry study Temperature ³99.5°F time entry study Any drug therapy within 7 day prior Study Day 0 ( except certain medication contraceptive , topical corticosteroid , infrequent use overthecounter headache medication , follow approval sponsor ) Blood donation excess 400 mL within 6 month time entry study Receipt immunoglobulin blood product within 60 day entry study Receipt investigational drug therapy standard vaccine within 120 day administration study drug protocol 60 day final dose study drug History immunodeficiency receipt immunosuppressive drug History allergic disease reaction likely exacerbate component study drug Previous medical history evidence intercurrent illness may compromise safety volunteer study Evidence systemic disease physical examination Evidence infection hepatitis A , B , C virus HIV1 At screen ( must within 7 day study dose administration ) follow : CBC : Hgb &lt; 12.0 gm/dL ; WBC &lt; 4,000/mm3 ; platelet count &lt; 120,000/mm3 ( laboratory normal value ) ; AST , ALT , BUN , creatinine &gt; upper limit normal ; abnormal laboratory value screen panel opinion principal investigator judge clinically significant . Nursing mother History alcohol drug abuse within past 2 year The presence condition concern opinion principal investigator may interfere conduct interpretation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>